The results of a number of clinical trials for the treatment of multiple myeloma with Zolinza were presented at the American Society of Hematology (ASH) 2010 annual meeting. The trials, ranging from Phase 1 to Phase 3, studied Zolinza in combination with a variety of approved myeloma drugs for the treatment of both early and advanced stages of the disease.

Zolinza (vorinostat) is manufactured by Merck Pharmaceuticals.  It is currently approved for a certain type of lymphoma and is being investigated as a treatment for multiple myeloma (see related Beacon …

A recent study showed that Velcade maintenance therapy modestly increased and deepened responses in elderly, newly diagnosed multiple myeloma patients after Velcade-based induction therapy. Maintenance therapy also caused small increases in the frequency of side effects.

Dr. Ruben Niesvizky of Weill Cornell Medical College in New York presented the study results at the American Society of Hematology (ASH) annual meeting in Orlando at the beginning of the month.

Prior to the recent development of novel therapeutic agents, the treatment for multiple myeloma was limited primarily to conventional chemotherapy and stem cell transplantation. …

Carfilzomib is well tolerated and highly active in both newly diagnosed multiple myeloma patients as well as re­lapsed and treat­ment-resistant patients, according to the results of two recent clinical trials that were presented at the American Society of Hematology 2010 annual meeting in Orlando earlier this month.

These results further underscore car­filz­o­mib’s activity in multiple myeloma.  Several studies with promising results were also reported in poster sessions during the annual meeting (see related Beacon news).

Like Velcade (bor­tez­o­mib), carfilzomib (Kyprolis), which is being developed by Onyx Pharmaceuticals, is a …

The re­­sults of three on­go­ing clin­i­cal trials sug­gest that elotuzumab in com­bi­na­tion with either Velcade (bor­tez­o­mib) or Revlimid (lena­lido­mide) plus low-dose dexamethasone (Decadron) is ef­fec­tive and well-tolerated in patients who have re­lapsed or have treat­ment-resistant mul­ti­ple myeloma.

The findings were pre­sented at the American Society of He­ma­tol­ogy (ASH) annual meeting in Orlando last week.

Elotuzumab is a new drug being devel­oped by Facet Biotech and Bristol-Myers Squibb as a po­ten­tial treat­ment for mul­ti­ple myeloma. It recog­nizes and binds to unique pro­teins on the surface …

The use of subcutaneous injections to deliver Velcade treatment is comparable in activity, but associated with fewer side effects, than the standard delivery of IV injections in multiple myeloma patients.

“We have similar efficacy with subcutaneous [injections] and a more convenient route of administration for patients, especially those with poor venous access. We don’t require IV central lines, and we do have, most importantly, a reduction in toxicities, which, in my opinion, is really important for our patients,” said Dr. Philippe Moreau, the lead investigator of the University Hospital in Nantes, France, …

Multipl miyelom hastalarında deri altı velcade enjeksiyonları standard damardan verilen velcade ile karşılaştırıldığında benzer etki gösterip çok daha az yan etkiye sebep olmuştur.

Fransa´nın Nantes Üniversitesi Hastanasi´nden baş araştırmacı Dr. Philippe Moreau çalışmasının sonuçlarını geçen hafta Orlando´da Amerikan Hematoloji Derneği´nin (ASH) konferansında sundu. Dr. Moreau: ¨Deri altı [enjeksiyon] tedavinin etkisi [damar altıyla karşılaştırıldığında] benzer sonuçlar gösteriyor, ve özellikle zor girilen damarları olan hastalarda çok daha rahat tedavi yapılıyor. Hastalarda kateter (sonda) gerekmiyor, ve de en önemlisi, toksisite azalıyor.¨

Avrupa´da ve Amerika´da velcade (bortezomib) şu anda damardan enjeksiyonlar için onaylanmıştır.

Ancak, damardan enjeksiyonlar …

This Monday was the third full day of the American Society of Hematology 2010 annual meeting, and it was packed with multiple myeloma-related presentations.  The Beacon published an update earlier today covering presentations made Monday morning.  This article covers material from Monday afternoon and evening.

The first presentation of the afternoon was by Dr. Ruben Niesvizky of the Weill Cornell Medical College in New York.  He reported on the results of a Phase 3 trial using Velcade (bor­tez­o­mib)-based initial treat­ment (induction) regi­mens com­bined with weekly Velcade main­te­nance ther­apy (abstract).

Patients in this trial were newly …